Verapamil
Half-Life (t½) PO: 5h · IV: 2.36h
Formula C27H38N2O4
Molecular Weight 454.6 g/mol
Aliases Calan, Isoptin Pharmacological Mechanism Non-dihydropyridine CCB — strongest cardiac (AV-nodal) effect of the class. Used for AF rate control, certain SVTs, hypertension, and migraine prophylaxis. Strong CYP3A4 + P-glycoprotein inhibitor → major DDI source. Constipation (~25%).
Half-Life & Elimination Curve (PO: 5h · IV: 2.36h) 100% 50% 25% 12.5% 0% 0h 0×t½ 5h 1×t½ 10h 2×t½ 15h 3×t½ 20h 4×t½ 25h 5×t½ 0×t½ (0h): 100% remaining (~0.282 mg/L) 1×t½ (5h): 50% remaining (~0.141 mg/L) 2×t½ (10h): 25% remaining (~70.5 µg/L) 3×t½ (15h): 12.5% remaining (~35.3 µg/L) 4×t½ (20h): 6.3% remaining (~17.6 µg/L) 5×t½ (25h): 3.1% remaining (~8.82 µg/L) Plasma (PO) t½ Decay (5h)
0×t½ 0h 100% (0.282 mg/L) 1×t½ 5h 50% (0.141 mg/L) 2×t½ 10h 25% (70.5 µg/L) 3×t½ 15h 12.5% (35.3 µg/L) 4×t½ 20h 6.3% (17.6 µg/L) 5×t½ 25h 3.1% (8.82 µg/L) Dosing Guidelines Oral (PO): Typical 240 mg (Range: 80–480 mg)Pharmacokinetic Parameters Oral (PO): Bioavailability (F): 25% · Volume of Distribution (Vd): 130 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h) [PMID 16898076 ]Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 130 L [PMID 16898076 ]Pathways It Modulates Target Organ Systems nervous Cardiovascular System digestive Interactions Simvastatin (major): CYP3A4 inhibition. Kantola 1998 (PMID:9728898): verapamil 240 mg/d × 2 d raised simvastatin AUC 4.6×, Cmax 2.6×, simvastatin acid AUC 2.8× (n=12 crossover). Limit simvastatin dose to 10 mg/d when co-administered with verapamil.Buspirone (caution): CYP3A4 inhibition. Lamberg 1998 (PMID:9663178) verbatim: "Verapamil and diltiazem increased the area under the buspirone plasma concentration-time curve [AUC (0-infinity)] 3.4-fold (p < 0.001) and 5.5-fold (p < 0.001), respectively". 9 healthy volunteers, randomized 3-phase crossover, verapamil 80 mg tid + 10 mg PO buspirone on d2. AUC 3.4×; Ki ≈ 0.5/2.4 = 0.208 µM. Cmax also 3.4× — substantial sedation amplification.Midazolam (caution): CYP3A4 inhibition. Backman 1994 (PMID:8198928) verbatim: midazolam AUC "increased from 12 +/- 1 microgram ml-1 min ... to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001)". 9 healthy volunteers, double-blind 3-phase crossover, verapamil 80 mg tid × 2d + 15 mg PO midazolam d2. AUC ratio 35/12 = 2.92×; Ki ≈ 0.5/1.92 = 0.260 µM. Cmax doubled, t½ prolonged, "profound and prolonged sedative effects" — dose reduction advised.Chemical Structure & Identifiers InChIKey: SGTNSNPWRIOYBX-UHFFFAOYSA-NSMILES: CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OCReferences Directory Compounds Registry Human Biology Hub